Autor según el artículo: Pérez-Cantero A, Serrano DR, Navarro-Rodríguez P, Schätzlein AG, Uchegbu IF, Torrado JJ, Capilla J

Departamento: Ciències Mèdiques Bàsiques

Autor/es de la URV: Capilla Luque, Javier / PÉREZ CANTERO, ALBA

Palabras clave: Supplementation Shiitake Resistance Posaconazole Oral delivery Necrosis-factor-alpha Molecular envelope technology Lipid nanoparticles Lentinula edodes Lentinan Hexose-correlated compound Fungus Fumigatus Formulations Chitosan Aspergillosis Amphotericin b Ahcc® Ahcc (r)

Resumen: Invasive pulmonary aspergillosis represents one of the most serious fungal infections among immunocompromised patients. In this study, we aimed to analyze the in vivo efficacy of prophylactic oral amphotericin B (AMB) encapsulated in modified chitosan-nanoparticles (Nanomerics' Molecular Envelope Technology (MET)) supplemented with a standardized extract of cultured Lentinula edodes mycelia (AHCC®) in a murine model of pulmonary aspergillosis. We determined fungal burden and survival of mice and additionally, we carried out a cytokine analysis in an attempt to understand the immunomodulation of the extract. Our results evidenced equivalent efficacy between orally administered AMB-MET and the intravenous liposomal AMB marketed formulation. Addition of the AHCC® supplement significantly improved efficacy in terms of burden reduction and survival increase of both oral and intravenous AMB therapies compared to the untreated control group. Moreover, a protective effect of the extract was observed in terms of weight loss. Regarding the cytokine profiles, the Th1 immune response was stimulated in treated animals when compared to the control group. This response was marked by an enhancement in the MCP-1, GM-CSF, VEGF, RANTES and IL-17 levels and a decrease in the IL-6, a biomarker related to the severity of the infection.

Áreas temáticas: Pharmacology & pharmacy Pharmaceutical science Medicina ii Farmacia Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Biotecnología

Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/

ISSN: 19994923

Direcció de correo del autor: javier.capilla@urv.cat

Identificador del autor: 0000-0002-0765-6403

Fecha de alta del registro: 2023-02-18

Volumen de revista: 11

Versión del articulo depositado: info:eu-repo/semantics/publishedVersion

Enlace a la fuente original: https://www.mdpi.com/1999-4923/11/9/456

URL Documento de licencia: http://repositori.urv.cat/ca/proteccio-de-dades/

Referencia al articulo segun fuente origial: Pharmaceutics. 11 (9):

Referencia de l'ítem segons les normes APA: Pérez-Cantero A, Serrano DR, Navarro-Rodríguez P, Schätzlein AG, Uchegbu IF, Torrado JJ, Capilla J (2019). Increased Efficacy of Oral Fixed-Dose Combination of Amphotericin B and AHCC® Natural Adjuvant against Aspergillosis. Pharmaceutics, 11(9), -. DOI: 10.3390/pharmaceutics11090456

DOI del artículo: 10.3390/pharmaceutics11090456

Entidad: Universitat Rovira i Virgili

Año de publicación de la revista: 2019

Tipo de publicación: Journal Publications